An investigation on behalf of investors of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) in connection with the proposed takeover was announced and NASDAQ:SCLN stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/23/2017 --An investigation on behalf of investors, who currently hold shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), was announced concerning whether the takeover of SciClone Pharmaceuticals, Inc. for $11.18 per share is unfair to NASDAQ:SCLN stockholders.

Investors who purchased shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and currently hold any of those NASDAQ:SCLN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain directors of SciClone Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ:SCLN investors in connection with the proposed acquisition.

On June 8, 2017, SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and a consortium consisting of entities affiliated with GL Capital Management GP Limited, Bank of China Group Investment Limited, CDH Investments, Ascendent Capital Partners and Boying (collectively, the "Buyer Consortium") announced that they have entered into a definitive merger agreement under which the Buyer Consortium will acquire all the outstanding shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for $11.18 per share in cash.

However, given that at least one analyst has set the high target price for NASDAQ:SCLN shares at $14.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:SCLN stockholders. More specifically, the investigation concerns whether the SciClone Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On June 22, 2017, NASDAQ:SCLN shares closed at $10.88 per share.

Those who are current investors in SciClone Pharmaceuticals, Inc. shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com